HIGH QUALITY SCIENTIFIC CONTENT,  ONLINE OPEN ACCESS,  GLOBAL SCIENTIFIC AUDIENCE,  COST EFFECTIVE, ANY ONE CAN DOWNLOAD REPRINTS 
Spreading knowledge

Google Scholar

Google Scholar

Archives

Back 

MONOCLONAL ANTIBODIES IN TREATMENT OF ASTHMA. Shiyana

MONOCLONAL ANTIBODIES IN TREATMENT OF ASTHMA.

Shiyana

International Journal of Natural Product Science 2012: Spl Issue 1:219.

Abstract(RBIP-219)

There are a number of antiasthmatic agents present in market including oral and inhaled corticosteroids, theophylline, long and short acting beta agonist, cromolyn, leucotriene antagonist, anticholinergics and immunotherapy. Most of these provide symptomatic relief which resulted in the emergence of biological agents for the treatment of asthma. These biological agents are monoclonal antibodies. Humanized monoclonal antibodies are targeted to specific inflammatory mediators such as IgE, interlukin-4, il-5 and tumour necrosis factor alpha. Monoclonal antibodies present a class of antiasthmatics which have the potency to modify remodeling of airways in severe asthma. Omalizumab is FDA approved monoclonal antibody for 12 years and older patients who have moderate to severe asthma. Other examples include Mepolizumab, infliximab, golimunab, daclizumab, pascloizumab, lumiliximab etc. Till today all of these proven to be free of any serious side effects but FDA approval is awaited.
Attachments:
Time to create page: 0.10 seconds


Copyright © All rights reserved Science Instinct Publications sciipub.com